Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.94 USD | +0.90% | -0.76% | +12.25% |
Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Apr. 03 | Oppenheimer Upgrades Aldeyra Therapeutics to Outperform From Perform, $10 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.25% | 234M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.31% | 22.2B | |
-16.53% | 21.23B | |
-8.40% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- ALDX Stock
- News Aldeyra Therapeutics, Inc.
- Aldeyra Says Reproxalap Demonstrates Symptom Improvement Over Xiidra in Mid-Stage Trial in Dry Eye Disease